Janus Henderson Group
NGM

Janus Henderson Group’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Janus Henderson Group’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-13,095
Closed -$33.9K – 2600
2023
Q2 		$33.9K Buy
13,095
+88
+0.7% +$314 ﹤0.01% 2590
2023
Q1 		$53K Buy
+13,007
New +$60.1K ﹤0.01% 2658

Other funds holding NGM

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group's NGM Position: Q3 2023 in Review

Janus Henderson Group sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q3 2023, closing a stake of 13,095 shares — an estimated $33.9K sold.

Janus Henderson Group first reported a position in NGM in Q1 2023 and held it in 2 quarters. The position peaked at $53K in Q1 2023. 94 funds tracked by Wall St. Rank hold NGM as of Q3 2023.

  • Janus Henderson Group reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Janus Henderson Group sold 13,095 NGM Biopharmaceuticals, Inc. Common Stock shares in Q3 2023, an estimated $33.9K.
  • Janus Henderson Group first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q1 2023 and held it in 2 quarters.
  • Janus Henderson Group's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $53K in Q1 2023.
  • 94 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q3 2023.

Based on Janus Henderson Group's 13F filing for Q3 2023, filed 14 Nov 2023.